Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parallel comparison of tenofovir and emtricitabine/tenofovir pre-exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples

Next Previous
Trial Profile

Parallel comparison of tenofovir and emtricitabine/tenofovir pre-exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PartnersPrEP

    • Most Recent Events

    • 26 Apr 2022 Results of a pooled participant-level data analysis ((iPrEx, VOICE and Partners PrEP studies) characterizing HIV-preventive, plasma tenofovir concentrations published in the Clinical Infectious Diseases
    • 11 Aug 2020 According to a Gilead Sciences media release, the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF).The approval of Truvada for PrEP was supported by data from two randomized, double-blind, placebo-controlled trials known as the Pre-Exposure Prophylaxis Initiative (iPrEx) and Partners PrEP.
    • 22 Aug 2016 According to a Gilead Sciences media release, the European Commission has granted marketing authorisation in the European Union (EU) for once daily Truvada (emtricitabine / tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired human immunodeficiency virus type 1 (HIV-1) infection in adults at high risk based on data from this and iPrEX (CTP 700022550) trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top